? FLOW CYTOMETRY SHARED RESOURCE (FCSR) Flow cytometry services are critical for cancer research. Since flow cytometry instrumentation is expensive, and typically requires significant technical expertise, a centralized resource is essential. The mission of the FCSR is to support OSUCCC members and high-impact cancer research projects with high quality cell analysis and sorting capabilities. The FCSR also provides training and regularly host technology-based seminars or workshops to introduce new technology to OSUCCC members. The FCSR continues to strive to be a state-of- the-art cell analysis laboratory that has the following Specific Aims to: 1) provide state-of-the-art equipment and support for high-quality cancer research for OSUCCC members on a fee-for-service basis; 2) continuously work with OSUCCC members to provide substantial technical expertise and training for state-of the-art cytometry instruments to address fundamental questions in cancer research so that researchers can have 24-hour access to flow cytometry instrumentation; and 3) introduce OSUCCC members to new instrumentation, technology and methodologies being developed at the FCSR through a variety of educational outreach activities. The FCSR co- Directors are Jeffrey Chalmers, (Department of Chemical and Biomolecular Engineering), and recently appointed co-Director, Kevin Weller, Associate Director of the Pelotonia Institute of Immuno-Oncology (PIIO) and specifically to develop the Immune Monitoring and Discovery Platform, a cross-cutting shared-resource initiative that integrates shared resources for complex immuno-oncology projects. Further, Dr. Gregory Behbehani (LR) is a Faculty Advisor for the Helios mass cytometer (CyTOF) system. Over the current grant cycle, major changes to the FCSR were to align with the establishment of the PIIO, which will result in a substantial increase in the need for flow cytometry services. To address this need, new instrumentation was purchased including four new instruments including a state-of-the-art Cytek Aurora flow cytometer and a Helios mass cytometer. During this time period, the FCSR contributed to 231 publications (39 >10 impact factor), had 296 users with 34,118 hours of service (83.7% to OSUCCC members), and supported 80 NCI grants (1 K12, 1 K22, 1 K24, 6 P01s, 1 P50, 52 R01s, 1 R03, 7 R21s, 3 R35s, 1 R37, 1 T32, and 5 U01s). In the next funding cycle, the FCSR will support the increasing needs of all OSUCCC strategic priorities, including immuno-oncology, translational genomics, cancer engineering, and cancer prevention and survivorship. The user base will substantially increased requiring new staff and technologies, for example by purchasing an additional Aurora instrument, and increasing cell sorting, cell isolation, and exosome/microvesicle research. In addition, new services under development include development of further exosome characterization and isolation technology. The annual budget of the FCSR is $518,075, yet the CCSG request is $108,261. As such, the FCSR leverages extensive institutional support and seeks only 20.9% support from CCSG funds.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016058-45
Application #
10090010
Study Section
Subcommittee H - Clinical Groups (NCI)
Project Start
1997-09-12
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Moshiri, Farzaneh; Salvi, Alessandro; Gramantieri, Laura et al. (2018) Circulating miR-106b-3p, miR-101-3p and miR-1246 as diagnostic biomarkers of hepatocellular carcinoma. Oncotarget 9:15350-15364
Petrov, Brawnie; Aldoori, Ayat; James, Cindy et al. (2018) Bipolar disorder in youth is associated with increased levels of vitamin D-binding protein. Transl Psychiatry 8:61
Senaras, Caglar; Niazi, Muhammad Khalid Khan; Sahiner, Berkman et al. (2018) Optimized generation of high-resolution phantom images using cGAN: Application to quantification of Ki67 breast cancer images. PLoS One 13:e0196846
Kovac, Rachel L; Ballash, Gregory; Fenger, Joelle et al. (2018) Plasma cytokeratin-18 concentrations as noninvasive biomarker of early gastrointestinal toxicosis in dogs receiving toceranib. J Vet Intern Med 32:2061-2068
Locke, Landon W; Kothandaraman, Shankaran; Tweedle, Michael et al. (2018) Use of a leukocyte-targeted peptide probe as a potential tracer for imaging the tuberculosis granuloma. Tuberculosis (Edinb) 108:201-210
Neff, Robert; Rush, Craig M; Smith, Blair et al. (2018) Functional characterization of recurrent FOXA2 mutations seen in endometrial cancers. Int J Cancer 143:2955-2961
Comiskey Jr, D F; Jacob, A G; Sanford, B L et al. (2018) A novel mouse model of rhabdomyosarcoma underscores the dichotomy of MDM2-ALT1 function in vivo. Oncogene 37:95-106
Dietrich, Sascha; Ole?, Ma?gorzata; Lu, Junyan et al. (2018) Drug-perturbation-based stratification of blood cancer. J Clin Invest 128:427-445
Chen, Zhong; Wu, Dayong; Thomas-Ahner, Jennifer M et al. (2018) Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13. Proc Natl Acad Sci U S A 115:6810-6815
Tallarico, Michael; Foster, Jared C; Seisler, Drew et al. (2018) Frequency and impact of grade three or four toxicities of novel agents on outcomes of older patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma (alliance A151611). J Geriatr Oncol 9:321-328

Showing the most recent 10 out of 2602 publications